Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
1372831 | Bioorganic & Medicinal Chemistry Letters | 2008 | 6 Pages |
SAR analysis performed with a limited set of cyclopentane-containing macrocycles led to the identification of N-[17-[2-(4-isopropylthiazole-2-yl)-7-methoxy-8-methylquinolin-4-yloxy]-13-methyl-2,14-dioxo-3,13-diazatricyclo [13.3.0.04,6]octadec-7-ene-4-carbonyl](cyclopropyl)sulfonamide (TMC435350, 32c) as a potent inhibitor of HCV NS3/4A protease (Ki = 0.36 nM) and viral replication (replicon EC50 = 7.8 nM). TMC435350 also displayed low in vitro clearance and high permeability, which were confirmed by in vivo pharmacokinetic studies. TMC435350 is currently being evaluated in the clinics.
Graphical abstractLead optimization performed on cyclopentane-containing macrocyclic hepatitis C virus NS3/4A protease inhibitors led to the identification of TMC435350, 32c, as a clinical candidate.Figure optionsDownload full-size imageDownload as PowerPoint slide